Abu Abraham, MD
Chief Medical Officer
Dr. Abu Abraham has over 20 years of pharmaceutical and clinical experience in ophthalmology and internal medicine. Before joining Cloudbreak Pharma, Abu held a range of R&D leaderships roles at Santen Pharmaceuticals, serving most recently as Vice President and Global Head of the Retina and Vitreous Therapeutic Area where he managed teams of preclinical researchers, clinical science medical directors, translational research scientists, and global product leaders. Earlier in his career at Santen, Abu served as the Global Head of Clinical Science, managing the clinical teams for all ophthalmic drug development programs. In addition, Abu also worked in drug safety and clinical development roles for Amgen, an internationally renowned pharmaceutical company.
Abu has extensive experience in ophthalmic drug development from early pre-clinical stages to Phase 1 through Phase 3 studies utilizing various therapeutic modalities, including small molecules, antibodies, and peptides. He also managed the group that initiated the first retinal gene therapy program at Santen, led the largest clinical development program to date in the orphan indication of posterior segment uveitis (700+ subjects), and chaired the R&D due diligence team for Santen’s in-licensing of a well-known advanced stage retinal cell therapy program.
We are excited to have Abu joining us, and we believe that with his drug development expertise and vast experience of working with multiple global regulatory authorities, Cloudbreak Pharma will further advance in global ophthalmology clinical research, as well as global product filing and registration.
